Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC.
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn’t This Tell Us? (BMIC-068)
By Editor